Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229418 | 0.86 | MAPT (0.35) | ALDH1A1PDE2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL759593 | 0.85 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2AATML3MBTL1 | |
| SCHEMBL231801 | 0.84 | MEN1 (0.34) | ALDH1A1MEN1KMT2AATML3MBTL1 | |
| SCHEMBL231494 | 0.81 | GAA (0.39) | ALDH1A1KMT2AL3MBTL1LMNAKDM4E | |
| SCHEMBL231942 | 0.76 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AATM | |
| SCHEMBL231789 | 0.72 | ALDH1A1 (0.34) | ALDH1A1CHRM5 | |
| SCHEMBL231495 | 0.67 | CYP3A4 (0.39) | MEN1KMT2AL3MBTL1KDM4EGAA | |
| SCHEMBL229419 | 0.65 | P2RX3 (0.35) | ALDH1A1MEN1KMT2AATML3MBTL1 | |
| SCHEMBL229979 | 0.64 | ALDH1A1 (0.34) | ALDH1A1CHRM5MEN1KMT2AATM | |
| SCHEMBL231943 | 0.64 | MEN1 (0.34) | ALDH1A1MEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004268-A1 | INSECTICIDAL COMPOSITIONS COMPRISING CYCLIC CARBONYLAMIDINES | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | US | claimed |
| EP-2587922-A1 | IMPROVED INSECTICIDAL COMPOSITIONS COMPRISING CYCLIC CARBONYLAMIDINES | Bayer Intellectual Property GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004268-A1 | INSECTICIDAL COMPOSITIONS COMPRISING CYCLIC CARBONYLAMIDINES | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2012000902-A1 | IMPROVED INSECTICIDAL COMPOSITIONS COMPRISING CYCLIC CARBONYLAMIDINES | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004268-A1 | INSECTICIDAL COMPOSITIONS COMPRISING CYCLIC CARBONYLAMIDINES | DDT, PRMT9, PNISR | ALDH1A1 4218/4885CHRM5 35/4885PDE2A 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.